Precision Therapeutics Launches New Website
May 31 2018 - 8:30AM
Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the
Company”), a company focused on applying artificial intelligence to
personalized medicine and drug discovery, announced today that it
has launched a new website: www.precisiontherapeutics.com. This new
site offers quick and easy access to essential information and
features while offering a more comprehensive understanding of the
Company's value proposition and strategic direction in the
precision medicine industry.
It has a clean uncluttered design, improved functionality and
enhanced content that better reflects the Company’s strategy to
develop highly customizable assessment methods for cancer patients.
It also provides information on its FDA-approved STREAMWAY® System
for automated, direct-to-drain medical fluid disposal. The new
website will be updated on a regular basis with news of business
activity, corporate milestones, events, and press releases.
Dr. Carl Schwartz, CEO of Precision Therapeutics, commented "We
are pleased to launch our new website which provides robust
information for the pharmaceutical, biotech and diagnostic
industries, as well as for investors, partners and media. We
believe that this new site will allow our visitors to better
understand Precision Therapeutics as we continue to grow and
increase our market presence. Precision Therapeutics is focused on
bringing precision medicine to the diagnosis and treatment of
cancer, by harnessing the power of artificial intelligence.
Our breakthroughs in gene, protein, and bioinformatics
techniques mean we can view the intricate interplay between the
genes and regulatory factors responsible for cancers. I would
encourage those who are interested in hearing more about our vision
to visit our new website: www.precisiontherapeutics.com.”
To be added to the Precision Therapeutics’ database, please
email Info@MoneyInfo-llc.com with your email address. This is
solely for the use of Precision Therapeutics and will not be sold
or distributed to third parties.
About Precision Therapeutics Inc.
Precision Therapeutics (NASDAQ:AIPT) operates in two
business areas: first, applying artificial intelligence to
personalized medicine and drug discovery to provide personalized
medicine solutions for clients in the pharmaceutical, diagnostic,
and biotech industries, and second, production of
the FDA-approved STREAMWAY® System for automated,
direct-to-drain medical fluid disposal.
Precision Therapeutics' CRO services business is committed
to improving the effectiveness of cancer therapy using the power of
artificial intelligence (AI) applied to rich disease data. This
business has launched with Precision
Therapeutics' investment in Helomics Corporation, a
precision diagnostic company and integrated clinical contract
research organization whose mission is to improve patient care by
partnering with pharmaceutical, diagnostic, and academic
organizations to bring innovative clinical products and
technologies to the marketplace. In addition to its
proprietary precision diagnostics for oncology, Helomics offers
boutique CRO services that leverage patient-derived tumor models,
coupled to a wide range of multi-omics assays (genomics, proteomics
and biochemical), and a proprietary bioinformatics platform
(D-CHIP) to provide a tailored solution to our client's specific
needs. Helomics is 25% owned by Precision Therapeutics.
Helomics® is headquartered in Pittsburgh,
Pennsylvania where the company maintains a state-of-the-art,
CLIA-certified, clinical and research laboratory. For more
information, please visit www.Helomics.com.
Precision Therapeutics has also announced the formation of a
subsidiary, TumorGenesis to pursue a new rapid approach to growing
tumors in the laboratory, which essentially “fools” the cancer
cells into thinking they are still growing inside the patient.
Precision Therapeutics and Helomics have also announced a
proposed joint venture with GLG Pharma focused on using
their combined technologies to bring personalized medicines and
testing to ovarian and breast cancer patients, especially those who
present with ascites fluid (over one-third of patients). The growth
strategy in this business includes securing new partnerships and
considering acquisitions in the precision medicine space.
Sold through the Skyline Medical business of Precision
Therapeutics, The STREAMWAY System virtually eliminates staff
exposure to blood, irrigation fluid and other potentially
infectious fluids found in the healthcare environment. Antiquated
manual fluid handling methods that require hand carrying and
emptying filled fluid canisters present an exposure risk and
potential liability. Skyline Medical's STREAMWAY System fully
automates the collection, measurement, and disposal of waste fluids
and is designed to: 1) reduce overhead costs to hospitals and
surgical centers; 2) improve compliance with OSHA and
other regulatory agency safety guidelines; 3) improve efficiency in
the operating room, and radiology and endoscopy departments,
thereby leading to greater profitability; and 4) provide greater
environmental stewardship by helping to eliminate the approximately
50 million potentially disease-infected canisters that go into
landfills each year in the U.S. For additional information,
please visit www.precisiontherapeutics.com.
Forward-looking Statements
Certain of the matters discussed in this announcement contain
forward-looking statements that involve material risks to and
uncertainties in the Company's business that may cause actual
results to differ materially from those anticipated by the
statements made herein. Such risks and uncertainties include (1)
risks related to the proposed merger, including the fact that we
may not complete the merger; we do not have complete information
about Helomics, including audited financial statements; the
combined company will not be able to continue operating without
additional financing; possible failure to realize anticipated
benefits of the merger; costs associated with the merger may be
higher than expected; the merger may result in disruption of the
Company’s and Helomics’ existing businesses, distraction of
management and diversion of resources; delay in completion of the
merger may significantly reduce the expected benefits; and the
market price of the Company’s common stock may decline as a result
of the merger; (2) risks related to our partnerships with other
companies, including the need to negotiate the definitive
agreements; possible failure to realize anticipated benefits of
these partnerships; and costs of providing funding to our partner
companies, which may never be repaid or provide anticipated
returns; and (3) other risks and uncertainties relating to the
Company that include, among other things, current negative
operating cash flows and a need for additional funding to finance
our operating plan; the terms of any further financing, which may
be highly dilutive and may include onerous terms; unexpected costs
and operating deficits, and lower than expected sales and
revenues; sales cycles that can be longer than expected,
resulting in delays in projected sales or failure to make such
sales; uncertain willingness and ability of customers to adopt new
technologies and other factors that may affect further market
acceptance, if our product is not accepted by our potential
customers, it is unlikely that we will ever become profitable;
adverse economic conditions; adverse results of any legal
proceedings; the volatility of our operating results and financial
condition; inability to attract or retain qualified senior
management personnel, including sales and marketing personnel; our
ability to establish and maintain the proprietary nature of our
technology through the patent process, as well as our ability to
possibly license from others patents and patent applications
necessary to develop products; the Company's ability to implement
its long range business plan for various applications of its
technology; the Company's ability to enter into agreements with any
necessary marketing and/or distribution partners and with any
strategic or joint venture partners; the impact of competition, the
obtaining and maintenance of any necessary regulatory clearances
applicable to applications of the Company's technology; and
management of growth and other risks and uncertainties that may be
detailed from time to time in the Company's reports filed with
the Securities and Exchange Commission, which are available
for review at www.sec.gov. This is not a solicitation to
buy or sell securities and does not purport to be an analysis of
the Company's financial position. See the Company's most recent
Annual Report on Form 10-K, and subsequent reports and other
filings at www.sec.gov.
Contacts:Investor RelationsKCSA Strategic
CommunicationsElizabeth Barker(212) 896-1203ebarker@kcsa.com
MONEYINFO, LLCCharles
Moskowitz617-827-1296info@moneyinfo-llc.com
Precision Therapeutics Inc. (NASDAQ:AIPT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Precision Therapeutics Inc. (NASDAQ:AIPT)
Historical Stock Chart
From Sep 2023 to Sep 2024